Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · October 15, 2019

Nivolumab vs Chemotherapy in Patients With Advanced Esophageal SCC Refractory or Intolerant to Previous Chemotherapy

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

The Lancet Oncology
Nivolumab Versus Chemotherapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2019 Sep 27;[EPub Ahead of Print], K Kato, BC Cho, M Takahashi, M Okada, CY Lin, K Chin, S Kadowaki, MJ Ahn, Y Hamamoto, Y Doki, CC Yen, Y Kubota, SB Kim, CH Hsu, E Holtved, I Xynos, M Kodani, Y Kitagawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated